Home > Pharmacotherapies for cannabis dependence.

Nielsen, Suzanne and Gowing, Linda and Sabioni, Pamela and Le Foll, Bernard (2019) Pharmacotherapies for cannabis dependence. Cochrane Database of Systematic Reviews, (1), Art. No.: CD008940. DOI: 10.1002/14651858.CD008940.pub2..

External website: https://www.cochranelibrary.com/cdsr/doi/10.1002/1...

There is incomplete evidence for all of the pharmacotherapies investigated, and for many outcomes the quality of the evidence was low or very low. Findings indicate that SSRI antidepressants, mixed action antidepressants, bupropion, buspirone and atomoxetine are probably of little value in the treatment of cannabis dependence. Given the limited evidence of efficacy, THC preparations should be considered still experimental, with some positive effects on withdrawal symptoms and craving. The evidence base for the anticonvulsant gabapentin, oxytocin, and N‐acetylcysteine is weak, but these medications are also worth further investigation.

Repository Staff Only: item control page